Seizures and Brain Tumors

Seminars in Oncology

Volumn 33, Issue 3, 2006, Pages 333-341

  Sperling, Michael R ^a,b   Ko, James ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE; BLEOMYCIN; BUSULFAN; CARBAMAZEPINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; METHOTREXATE; NITROSOUREA; OXCARBAZEPINE; PACLITAXEL; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TENIPOSIDE; THIOTEPA; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VINBLASTINE; ZONISAMIDE;

AGRANULOCYTOSIS; ALOPECIA; ANHIDROSIS; APLASTIC ANEMIA; ARTHRITIS; ARTICLE; ATAXIA; BEHAVIOR DISORDER; BONE MARROW SUPPRESSION; BRAIN TUMOR; CANCER DIAGNOSIS; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; DEPRESSION; DIPLOPIA; DIZZINESS; DROWSINESS; DRUG EFFICACY; DYSTONIA; EYE DISEASE; FATIGUE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GLAUCOMA; HEADACHE; HUMAN; HYPERAMMONEMIA; HYPERSENSITIVITY; HYPONATREMIA; INSOMNIA; IRRITABILITY; KIDNEY FAILURE; LIVER FAILURE; MYOCLONUS; NAUSEA; NEPHROLITHIASIS; NERVOUSNESS; NYSTAGMUS; PARESTHESIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PSEUDOLYMPHOMA; PSYCHOMOTOR RETARDATION; PSYCHOSIS; RASH; RISK ASSESSMENT; SEDATION; SEIZURE; SHOULDER HAND SYNDROME; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TERATOGENICITY; THEORETICAL STUDY; THROMBOCYTOPENIA; TIC; TOXIC EPIDERMAL NECROLYSIS; TREMOR; VASCULITIS; VERTIGO; VITAMIN DEFICIENCY; VOMITING; WEIGHT GAIN;

ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DRUG INTERACTIONS; GLUCOCORTICOIDS; HUMANS; RISK FACTORS; SEIZURES;

EID: 33744916983     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.03.009     Document Type: Article

References (57)

1. Posner J.B. Neurologic Complications of Cancer (1995), Davis, Philadelphia, PA
2. Penfield W., Ericson T.C., and Tarlov I. Relation of intracranial tumors and symptomatic epilepsy. Arch Neurol Psychiatry 44 (1940) 300-315
3. Cohen N., Strauss G., Lew R., et al. Should prophylactic anticonvulsants be administered to patients with newly-diagnosed cerebral metastases? A retrospective analysis. J Clin Oncol 6 (1988) 1621-1624
4. Moots P.L., Maciunas R.J., Eisert D.R., et al. The course of seizure disorders in patients with malignant gliomas. Arch Neurol 52 (1995) 717-724
5. Glantz M.J., Cole B.F., Friedberg M.H., et al. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 46 (1996) 985-991
6. Glantz M.J., Cole B.F., Forsyth P.A., et al. Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54 (2000) 1886-1893
7. Le Blanc F.E., and Rasmussen T. Cerebral seizures and brain tumors. In: Vinken P.J., and Bruyun G.W. (Eds). Handbook of Clinical Neurology vol 16 (1973), North Holland, Amsterdam, the Netherlands 295-301
8. Mahaley M.S., and Dudka L. The role of anticonvulsant medications in the management of patients with anaplastic gliomas. Surg Neurol 16 (1981) 399-401
9. Wen P.Y., and Marks P.W. Medical management of patients with brain tumors. Curr Opin Oncol 14 (2002) 299-307
10. Schaller B., and Ruegg S.J. Brain tumor and seizures. Pathophysiolosy and its implication for treatment revisited. Epilepsia 44 (2003) 1223-1232
11. Batchelor T., and DeAngelis L.M. Medical management of cerebral metastases. Neurosurg Clin 7 (1996) 435-446
12. Hildebrand J.H., Lecaille C., Perennes J.P., et al. Epileptic seizures during follow-up of patients treated for primary brain tumor. Neurology 65 (2005) 212-215
13. Central Brain Tumor Registry of the Unitied States; 2004-2005 Statistical Report; 1997-2001 years data collected. http://www.cbtrus.org/reports/reports.html
14. Arnold S.M., and Patchell R.A. Diagnosis and management of brain metastases. Hematol Oncol Clin North Am 15 (2001) 1085-1107
15. Ketz E. Brain tumors and epilepsy. In: Vinken P.J., and Bruyn G.W. (Eds). Handbook of Clinical Neurology vol 16 (1974), Elsevier Science, New York, NY 254-269
16. White J.C., Liu C.T., and Mixter W.J. Focal epilepsy: A statistical study of its causes and the results of surgical treatment. I. Epilepsy secondary to intracranial tumors. N Engl J Med 438 (1948) 891-899
17. Glantz M., and Recht L. Epilepsy in the cancer patient. Neurological disorders in systemic cancer. In: Vinken P.J., and Bruyun G.W. (Eds). Handbook of Clinical Neurology vol 69 (1997), North Holland, Amsterdam, the Netherlands 9-18
18. Cascino G.D. Epilepsy and brain tumors. Implications for treatment. Epilepsia 31 suppl 3 (1990) S37-S44
19. Byrne T.N., Cascino T.L., and Posner J.B. Brain metastasis from melanoma. J Neurooncol 1 (1983) 313-317
20. Whittle I.R., and Beaumont A. Seizures in patients with supratentorial oligodendroglial tumours. Clinicopathological features and management considerations. Acta Neurochir 135 (1995) 19-24
21. North J.B., Penhall R.K., Hanieh A., et al. Phenytoin and postoperative epilepsy. A double-blind study. J Neurosurg 58 (1983) 672-677
22. Franceschetti S., Binelli S., Casazza M., et al. Influence of surgery and antiepileptic drugs on seizures symptomatic of cerebral tumours. Acta Neurochir 103 (1990) 47-51
23. Deutschman C.S., and Haines S.J. Anticonvulsant prophylaxis in neurological surgery. Neurosurgery 17 (1985) 510-517
24. Boarini D.J., Beck D.W., and VanGilder J.C. Postoperative prophylactic anticonvulsant therapy in cerebral gliomas. Neurosurgery 16 (1985) 290-292
25. Sirven J.I., Wingerchuk D.M., et al. Seizure prophylaxis in patients with brain tumors. A meta-analysis. Mayo Clin Proc 79 (2004) 1489-1494
26. Lee S.T., Lui T.N., Chang C.N., et al. Prophylactic anticonvulsants for prevention of immediate and early postcraniotomy seizures. Surg Neurol 31 (1989) 361-364
27. Siomin V., Angelov L., Li L., et al. Results of a survey of neurosurgical practice patterns regarding the prophylactic use of anti-epilepsy drugs in patients with brain tumors. J Neurooncol 74 (2005) 211-215
28. De Santis A., Villani R., Sinisi M., et al. Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors. A randomized controlled study. Epilepsia 43 (2002) 175-182
29. Sperling M.R. The consequences of uncontrolled epilepsy. CNS Spectrums 9 (2004) 98-109
30. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62 (2004) 1252-1260
31. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62 (2004) 1261-1273
32. Delattre J., Safai B., and Posner J.B. Erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and phenytoin. Neurology 38 (1988) 194-198
33. Mattson R.H., Cramer J.A., Collins J.F., et al. A comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 313 (1985) 145-151
34. Mattson R.H., Cramer J.A., Collins J.F., et al. A comparison of valproate and carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 327 (1992) 765-771
35. Gattis W.A., and May D.B. Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents. A case report and review. Ann Pharmacother 30 (1996) 520-526
36. Beaumont A., and Whittle I.R. The pathogenesis of tumour associated epilepsy. Acta Neurochir 142 (2000) 1-15
37. Finchum R.W., and Schottelius D.D. Decreased phenytoin levels in antineoplastic therapy. Ther Drug Monit 1 (1979) 277-283
38. Bollini P., Riva R., and Albani F. Decreased phenytoin levels during anitineoplastic therapy. A case report. Epilepsia 24 (1980) 75-78
39. Sylvester R.K., Lewis F.B., Caldwell K.C., et al. Impaired phenytoin bioavailability secondary to cisplatinum, vinblastine and bleomycin. Ther Drug Monit 6 (1984) 302-305
40. Ghosh C., Lazarus H.M., Hewlett J.S., et al. Fluctuation of serum phenytoin concentrations during autologous bone marrow transplant for primary central nervous system tumors. J Neurooncol 12 (1992) 25-32
41. Neef C., and de Voogd-van der Straaten J. An interaction between cytostatic and anticonvulsant drugs. Clin Pharmacol Ther 43 (1988) 372-375
42. Grossman S.A., Hochberg F., Fisher J., et al. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. Cancer Chemother Pharmacol 42 (1998) 118-126
43. Grossman S.A., Sheilder V.R., and Gilbert M.R. Decreased phenytoin levels in patients receiving chemotherapy. Am J Med 87 (1989) 505-510
44. Dofferhoff A.S.M., Berendsen H.H., Naalt J., et al. Decreased phenytoin level after carboplatin treatment. Am J Med 89 (1990) 247-248
45. Warren R.D., and Bender A.R. Drug interactions with antineoplastic agents. Cancer Treat Rep 61 (1977) 1231-1241
46. Reich S.D., and Bachur N.R. Alterations in Adriamycin efficacy by phenobarbital. Cancer Res 36 (1976) 3803-3806
47. Fitzsimmons W.E., Ghalie R., and Kaizer H. The effect of hepatic enzyme inducers on busulfan neurotoxicity. Cancer Chemother Pharmacol 27 (1990) 226-228
48. Baker D.K., Relling M.V., Pui C.-H., et al. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol 10 (1992) 311-315
49. Chang S.M., Kuhn J.G., Rizzo J., et al. Phase I study of paclitaxel in patients with recurrent malignant gliomas. A North American Brain Tumor Consortium report. J Clin Oncol 16 (1998) 2188-2194
50. Chang T.K., Chen G., and Waxman D.J. Modulation of thiotepa antitumor activity in vivo by alteration of liver cytochrome P450-catalyzed drug metabolism. J Pharmacol Exp Ther 274 (1995) 270-275
51. Fetell M.R., Grossman S.A., Fisher J.D., et al. Preirradiation paclitaxel in glioblastoma multiforme. Efficacy, pharmacology, and drug interactions. J Clin Oncol 15 (1997) 3121-3128
52. Muller P.J., Tator C.H., and Bloom M. The effect of phenobarbital on the toxicity and tumoricidal activity of CCNU in a murine brain tumor model. J Neurosurg 52 (1980) 359-366
53. Wong D.D., Longenecker R.G., et al. Phenytoin-dexamethasone. A possible drug-drug interaction. JAMA 254 (1985) 2062-2063
54. Lackner T.E. Interaction of dexamethasone with phenytoin. Pharmacotherapy 11 (1991) 344-347
55. Haque N., Thrasher K., and Werk E. Studies on dexamethasone metabolism in man. Effect of diphenylhydantoin. J Clin Endocrinol Metab 34 (1972) 44-50
56. Chalk J.B., Ridgeway K., Brophy T., et al. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. J Neurol Neurosurg Psychiatry 47 (1984) 1087-1090
57. Riviello J.J., Honavar M., and Holmes B.L. Tumors and partial seizures. In: Oxbury J., Polkey C., and Duchowny M. (Eds). Intractable Focal Epilepsy (2000), Saunders, London, UK 195-212